Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…
Rheumatologist Rachelle Buchbinder, AO, MBBS (Hons), MSc, PhD, discusses reducing overdiagnosis, overtreatment, low-value care and waste in medicine.
At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Benjamin Widener, MD, FACP, has found a niche in community practice rheumatology in his hometown in Wyoming. As the lone rheumatologist serving the community, he has the opportunity to develop lasting therapeutic relationships.
Dr. Mrinalini Dey of London was invited to present her research at the 2023 Rheumatology Research Workshop in Orlando. She describes the experience here.
Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
A proposal for biosimilar use in the 2025 budget would allow substitution of any biosimilar for its reference product without an interchangeable designation. The hope is to increase biosimilar uptake, with the subsequent potential to increase product “competition, access and affordability.”1 In the 2025 budget proposal, the Biden administration noted that the legal distinction between…